3/21
08:00 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Raymond James. They set an "outperform" rating and a $45.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Raymond James. They set an "outperform" rating and a $45.00 price target on the stock.
3/21
08:00 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Raymond James. They set an "outperform" rating and a $45.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Raymond James. They set an "outperform" rating and a $45.00 price target on the stock.
3/20
06:26 am
bbio
Rating for BBIO
Low
Report
Rating for BBIO
3/19
08:34 am
bbio
Rating for BBIO
Low
Report
Rating for BBIO
3/11
09:14 am
bbio
Rating for BBIO
Low
Report
Rating for BBIO
3/5
08:08 am
bbio
Rating for BBIO
Medium
Report
Rating for BBIO
3/5
08:08 am
bbio
Rating for BBIO
Medium
Report
Rating for BBIO
3/4
08:06 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.
Medium
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.
2/23
11:28 am
bbio
Rating for BBIO
Low
Report
Rating for BBIO
2/23
11:28 am
bbio
Rating for BBIO
Low
Report
Rating for BBIO
1/31
08:07 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating and a $37.00 price target on the stock.
Medium
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at BMO Capital Markets. They set a "market perform" rating and a $37.00 price target on the stock.
1/31
06:00 am
bbio
Rating for BBIO
Medium
Report
Rating for BBIO
1/31
06:00 am
bbio
Rating for BBIO
Medium
Report
Rating for BBIO
1/22
09:09 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock.
1/22
08:45 am
bbio
Rating for BBIO
Low
Report
Rating for BBIO